2 Under-$50 Stocks to Own for Decades, and the 6.4% Yielder We Turn Down

Every few weeks the same list cycles through: stocks trading "under $50" that a retail investor can supposedly own for decades. The screen rests on a confusion. A share price is just the market cap divided by the number of shares; it tells you nothing about whether the business earns more cash than it pays out, or whether it can keep doing so in a bad year. Three companies below trade under $50, and all three screen as "cheap" on some popular metric. That is where the resemblance ends.

The test that separates them has nothing to do with the price tag. It is whether the dividend or distribution is covered by cash the business keeps generating, and whether the balance sheet can carry that payout through a downturn without a cut. Run that test on this shelf and the sorting is unambiguous: two names earn a decades-long slot, and the one with the highest yield on paper is the one we would turn down.

Enterprise Products Partners (EPD): the payout that has never broken

Enterprise Products is the model answer, and the business is ideal for the test. Pipelines and terminals charge fees on volumes, so the cash arrives whether oil and gas prices rise or fall. In the second quarter the system moved a record 14.7 million barrels a day of equivalent pipeline volumes, up 8%, with marine terminal volumes up 33%, and it generated a record $2.83 billion of adjusted EBITDA, up 17% from a year earlier. Net income attributable to common unitholders came to $1.84 billion, $0.84 per unit, a 28% gain.

The coverage math is where the test does its work. Enterprise paid $1.2 billion in cash distributions in the quarter but produced $2.3 billion of distributable cash flow — coverage of 1.9x — and retained the other $1.1 billion to fund new pipelines instead of borrowing to build them. That is what a durable income position looks like: the payout is not merely covered, it is covered by a wide margin, and growth is self-funded.

The quarterly distribution is now $0.56 per unit, $2.24 annualized, a 2.8% increase that extends a streak of 28 consecutive years of annual raises, which co-CEO Randy Fowler calls the longest of any U.S. midstream company. The streak is the reason the stock is worth a decades-long slot. Enterprise raised its distribution through the 2016 oil bust and raised it again through 2020, when midstream rivals were cutting, and it has never reduced the payout in its history. Debt is light for the coverage: $33.5 billion of principal against a reported net leverage of 3.2x adjusted EBITDA, carrying through a downturn without strain. At roughly $38 the units yield about 5.8%, and this year's 19% gain has carried the price to the top of a 52-week range of roughly $30 to $40. It is an income anchor, not a turnaround.

Energy Transfer (ET): the tempting neighbor we turn down

On the same shelf, paying more, sits the name this screen wants you to buy. Energy Transfer yields about 6.4%, has raised its distribution for 19 consecutive quarters, and reported strong recent numbers: second-quarter adjusted EBITDA of $5.07 billion, up 31%, with 2026 guidance raised to $18.8–$19.1 billion. Nothing about today's operation is broken.

The gate is what happened the last time the environment broke. In late 2020 Energy Transfer cut its quarterly distribution from $0.305 to $0.1525 — an annualized rate of $0.61, exactly half — at a moment when its pipeline assets had not stopped earning. Pipeline volumes did not collapse; the balance sheet did the cutting. The payout has been rebuilt since: the $0.34 quarterly distribution today, $1.36 annualized, is the product of those 19 consecutive increases, but the streak began roughly five years ago, rising from the floor of a cut. Enterprise, by contrast, never interrupted a single raise through the same downturn.

The balance sheet points the same direction. Energy Transfer carries about $68 billion of long-term debt against an EBITDA base it guides to roughly $19 billion this year — around 3.6x, before current maturities and leases — versus Enterprise at 3.2x with barely half the debt. The leverage is manageable today; that is not the objection. The objection is that for the specific job being offered — a distribution you can bank for decades without re-underwriting each year — Energy Transfer has already demonstrated, at a higher leverage ratio, that it will cut the payout when the market turns. The extra 60 basis points of yield is the market's payment for that demonstrated fragility, and it is not enough. It is the difference between a compounder and a project that needs monitoring, and we will not put a monitored payout in the decades slot. We turn Energy Transfer down.

Pfizer (PFE): the yield that looks reckless and checks out in cash

The harder case, and the one that rewards doing the arithmetic, is Pfizer. The stock yields about 6% on a $0.43 quarterly dividend, and headline financials make the payout look indefensible: reported earnings of the trailing twelve months put the price at about 38x earnings and the payout ratio above 200% — the accounting says Pfizer distributes more than twice what it earns. That is a reported-artifact, not a cash number. Most of the earnings drag is non-cash: amortization from the $43 billion Seagen acquisition and related impairments. The cash flow statement tells the real story: trailing free cash flow of about $11 billion covers a dividend bill of roughly $9.8 billion — about 1.1x. Not a fortress, but covered, on operating cash flow of $13.4 billion.

The reason the yield is 6% in the first place is the patent cliff. Revenue has fallen from more than $100 billion in 2022 to $62.6 billion in the latest reported year as COVID demand evaporated, and Eliquis, Ibrance, and Xtandi — more than $20 billion of combined annual sales — lose exclusivity over the next couple of years, on top of a broader loss-of-exclusivity wave through 2030. Borrowing has roughly doubled from the end of 2022 to about $61 billion of long-term debt to fund acquisitions meant to refill the pipeline. The market is pricing that decline into a stock at roughly 14x forward earnings.

That is what makes the position coherent. At $28.50 you are being paid about 6% a year to hold through the patent-cliff trough, and the falsifiable condition is the same coverage test used above: if free cash flow keeps covering the dividend as revenue bottoms out, and Pfizer keeps growing the payout at the roughly 2.5% annualized pace of recent years on a record of 351 consecutive quarterly payments, the compounding works and the decades label is earned. If coverage falls below one times without an offsetting improvement in debt capacity, the thesis breaks and the holding loses its reason to exist. This is a value-repair holding priced for a long, hard transition — not a sleep-at-night anchor — and the difference between the two is stated plainly rather than buried.

The rule

The $50 cutoff is wallpaper. Underneath it, the sorting principle is narrow and repeatable: is the payout covered, is the covering cash durable, and can the balance sheet survive the bad year before we trust the good ones? Enterprise Products passes on every count and sits in the income-anchor slot. Pfizer passes conditionally, and earns the repair slot with its monitoring condition stated in cash terms. Energy Transfer is turned down — not because it is failing today, but because for the job of a decades-long hold, the higher-yield neighbor has already shown, in the last downturn, exactly what it does when the market breaks. In a yield race the highest yielder usually wins the screen and loses the hold. That, not the number before the decimal point, is the decision an investor is actually making.